AbbVie presents 22 IBD abstracts; stock pre-market at EUR 247.15, plus 0.59 percent
Published on 10/12/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- AbbVie announced 22 IBD abstracts for the ACG 2026 meeting.
- The stock was at EUR 247.15 pre-market at Lang & Schwarz.
- The price was 0.59 percent above the October 9 Xetra close.
AbbVie announced 22 scientific abstracts for the American College of Gastroenterology’s 2026 Annual Scientific Meeting on October 11, 2026. At 8:09 a.m. CEST on October 12, 2026, the stock was at EUR 247.15 in pre-market trading at Lang & Schwarz, 0.59 percent above the Xetra close of October 9, 2026, at EUR 245.70.
Pre-market trading
The Lang & Schwarz bid was EUR 246.60 and the ask was EUR 247.70. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.
What matters today
The ACG meeting runs through October 14, 2026, with AbbVie’s highlighted oral presentation scheduled for October 13 at 2:15 p.m. CDT. A EUR 250.00 round-number level is 1.15 percent above EUR 247.15. AbbVie’s October 11 release cites 22 abstracts to be presented at ACG 2026.
Inflammatory bowel disease data
PR Newswire reported that AbbVie’s presentation program includes Phase 3 AFFIRM results for SKYRIZI in Crohn’s disease, long-term analyses and real-world evidence for RINVOQ. The release said AFFIRM showed higher clinical remission and endoscopic response rates versus placebo at Week 12.
Market context: Market report S&P 500.
